Publication:
An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000

dc.contributor.authorElizabeth A. Ashleyen_US
dc.contributor.authorJudith Rechten_US
dc.contributor.authorArlene Chuaen_US
dc.contributor.authorDavid Danceen_US
dc.contributor.authorMehul Dhordaen_US
dc.contributor.authorNigel V. Thomasen_US
dc.contributor.authorNisha Ranganathanen_US
dc.contributor.authorPaul Turneren_US
dc.contributor.authorPhilippe J. Guerinen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.authorNicholas P. Dayen_US
dc.contributor.otherLondon School of Hygiene & Tropical Medicineen_US
dc.contributor.otherUniversity of Oxforden_US
dc.contributor.otherImperial College Londonen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherTan Tock Seng Hospitalen_US
dc.contributor.otherLao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU)en_US
dc.contributor.otherMyanmar Oxford Clinical Research Uniten_US
dc.contributor.otherAngkor Hospital for Childrenen_US
dc.date.accessioned2019-08-28T06:03:40Z
dc.date.available2019-08-28T06:03:40Z
dc.date.issued2018-07-01en_US
dc.description.abstract© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. Low- and middle-income countries (LMICs) shoulder the bulk of the global burden of infectious diseases and drug resistance. We searched for supranational networks performing antimicrobial resistance (AMR) surveillance in LMICs and assessed their organization, methodology, impacts and challenges. Since 2000, 72 supranational networks for AMR surveillance in bacteria, fungi, HIV, TB and malaria have been created that have involved LMICs, of which 34 are ongoing. The median (range) duration of the networks was 6 years (1-70) and the number of LMICs included was 8 (1-67). Networks were categorized as WHO/governmental (n=26), academic (n=24) or pharma initiated (n=22). Funding sources varied, with 30 networks receiving public or WHO funding, 25 corporate, 13 trust or foundation, and 4 funded from more than one source. The leading global programmes for drug resistance surveillance in TB, malaria and HIV gather data in LMICs through periodic active surveillance efforts or combined active and passive approaches. The biggest challenges faced by these networks has been achieving high coverage across LMICs and complying with the recommended frequency of reporting. Obtaining high quality, representative surveillance data in LMICs is challenging. Antibiotic resistance surveillance requires a level of laboratory infrastructure and training that is not widely available in LMICs. The nascent Global Antimicrobial Resistance Surveillance System (GLASS) aims to build up passive surveillance in all member states. Past experience suggests complementary active approaches may be needed in many LMICs if representative, clinically relevant, meaningful data are to be obtained. Maintaining an up-to-date registry of networks would promote a more coordinated approach to surveillance.en_US
dc.identifier.citationJournal of Antimicrobial Chemotherapy. Vol.73, No.7 (2018), 1737-1749en_US
dc.identifier.doi10.1093/jac/dky026en_US
dc.identifier.issn14602091en_US
dc.identifier.issn03057453en_US
dc.identifier.other2-s2.0-85050250365en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/46580
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85050250365&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleAn inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000en_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85050250365&origin=inwarden_US

Files

Collections